Clearside Biomedical receives additional $3M from Healthcare Royalty; reduces royalty cap

Clearside Biomedical, Inc.

Company entered Omnibus Amendment with Healthcare Royalty Partners; received $3.0M for remaining SCS Microinjector assets.
Royalty threshold for expiration reduced from $110.5M to $106.5M; potential lower future payments.
Purchaser waived right to foreclose on Seller capital stock in specified circumstances.
All other terms of original 2022 Purchase/Sale and Contribution Agreements remain unchanged.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.